Bladder Cancer

Papers
(The TQCC of Bladder Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives12
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer11
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models10
Urologists and Advanced Practice Providers Evaluating Hematuria9
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort9
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer8
Clinical Trials Corner Issue 9(2)8
Comparison of Robotic vs Open Cystectomy: A Systematic Review7
Standard vs extended lymphadenectomy for muscle invasive bladder cancer7
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder6
Management of bladder cancer in kidney transplant recipients: A narrative review6
Expression of PD-1 and PD-L1 in BCG-treated NMIBC6
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization6
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter6
Clinical Trials Corner Issue 10(2)5
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review5
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer5
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It5
Organoid models in bladder cancer: From bench to bedside?5
A New Standard of Care for Bladder Cancer5
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors4
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes4
Y Chromosome Loss and Bladder Cancer3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma3
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy3
Challenging Cases in Urothelial Cancer: Case 263
Challenging Cases in Urothelial Cancer: Case 333
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?3
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors3
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Commentary on Novitas LCD3
Clinical Trials Corner Issue 8(2)3
Challenging Cases in Urothelial Cancer: Case 273
0.36367988586426